Dapirolizumab pegol
- Generic Name
- Dapirolizumab pegol
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1416147-64-2
- Unique Ingredient Identifier
- N4606MB5HM
- Background
Dapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- UCB Biopharma SRL
- Target Recruit Count
- 760
- Registration Number
- NCT04976322
- Locations
- 🇺🇸
Sl0046 50273, Las Vegas, Nevada, United States
🇵🇱Sl0046 40090, Poznan, Poland
🇨🇳Sl0046 20113, Taichung City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath